Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.

Article Details

Citation
Copy to clipboard

Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M

Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.

Int J Antimicrob Agents. 2011 Jan;37(1):39-45. doi: 10.1016/j.ijantimicag.2010.08.021.

PubMed ID
21075602 [ View in PubMed
]
Abstract

Solithromycin (CEM-101) is a novel fluoroketolide with high potency against Gram-positive and Gram-negative bacteria commonly associated with community-acquired respiratory tract infections and skin and skin-structure infections. In this study, solithromycin and comparator antimicrobials were tested against a contemporary collection of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, Enterococcus faecium and other Enterococcus spp. collected in the SENTRY Antimicrobial Surveillance Program. Solithromycin was active against S. aureus [minimum inhibitory concentration for 50% of the organisms (MIC(50))=0.12 mug/mL] and was two-fold more active than telithromycin (MIC(50)=0.25 mug/mL). Solithromycin was more potent against methicillin (oxacillin)-susceptible S. aureus [MIC(50)=0.06 mug/mL and MIC for 90% of the organisms (MIC(90))=0.12 mug/mL) compared with methicillin (oxacillin)-resistant S. aureus (MIC(50)=0.12 mug/mL and MIC(90)>16 mug/mL). Solithromycin activity was reduced amongst heterogeneous vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus (MIC(50)>16 mug/mL). Against strains with defined susceptibilities to erythromycin, clindamycin and telithromycin, solithromycin showed potent inhibition against all combinations (MIC(50)=0.06 mug/mL) except those with non-susceptibility to telithromycin (>2 mug/mL) (MIC(50)>16 mug/mL). The solithromycin MIC(50) for E. faecium (1 mug/mL) was four-fold higher than the MIC(50) for E. faecalis (0.25 mug/mL). In summary, solithromycin demonstrated high potency against many Staphylococcus and Enterococcus spp. isolated from contemporary infections worldwide.

DrugBank Data that Cites this Article

Drugs